Most of the Effect of Paroxetine for Treating Hot Flashes May Be Placebo Effect
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 5, 2023 -- Most of the efficacy of paroxetine to treat hot flashes may be a placebo effect, according to a review published online Aug. 4 in Frontiers in Psychiatry.
Joshua R. Rhodes, Ph.D., from Abilene Christian University in Texas, and colleagues conducted a systematic literature review to identify randomized clinical trials examining the efficacy of paroxetine to treat hot flashes.
Six randomized clinical trials (1,486 women) were included in a meta-analysis.
The researchers found that 79 percent of the mean treatment response for hot flash frequency was accounted for by a placebo response, resulting in a mean true drug effect of 21 percent at most across the six trials. For hot flash severity, 68 percent of the mean treatment response was accounted for by a placebo response, resulting in a maximum true drug effect of 32 percent.
“The findings provide evidence to reevaluate the use of paroxetine to treat postmenopausal hot flashes and emphasize the importance of considering effective, alternative treatments for vasomotor symptoms,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Risk for Depressive Symptoms Increased for Perimenopausal Women
THURSDAY, May 9, 2024 -- Perimenopausal women have an increased risk for depressive symptoms and diagnoses, according to a review published in the July 15 issue of the Journal of...
Surgical Premature Menopause Tied to Risk for Muscle Disorders
TUESDAY, May 7, 2024 -- Women experiencing surgical premature menopause (PM) have a higher likelihood of developing musculoskeletal disorders, according to a study published...
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.